TWI744963B - 作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 - Google Patents
作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 Download PDFInfo
- Publication number
- TWI744963B TWI744963B TW109121289A TW109121289A TWI744963B TW I744963 B TWI744963 B TW I744963B TW 109121289 A TW109121289 A TW 109121289A TW 109121289 A TW109121289 A TW 109121289A TW I744963 B TWI744963 B TW I744963B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- general formula
- methoxy
- chloro
- methoxyphenyl
- Prior art date
Links
- 0 COc1cc(NC(C(c2c[n]c(c(*)c3*)c2cc3I)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 Chemical compound COc1cc(NC(C(c2c[n]c(c(*)c3*)c2cc3I)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 0.000 description 3
- YFBBTZYVYMKKMH-UHFFFAOYSA-N COc1cc(NC(C(c(c2c3)c[nH]c2cc(OC)c3F)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 Chemical compound COc1cc(NC(C(c(c2c3)c[nH]c2cc(OC)c3F)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 YFBBTZYVYMKKMH-UHFFFAOYSA-N 0.000 description 1
- FPNUJANICIQZCF-UHFFFAOYSA-N COc1cc(NC(C(c(c2c3)c[nH]c2cc(OC)c3OC(F)(F)F)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 Chemical compound COc1cc(NC(C(c(c2c3)c[nH]c2cc(OC)c3OC(F)(F)F)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 FPNUJANICIQZCF-UHFFFAOYSA-N 0.000 description 1
- YTAWZGPWZPPXCQ-UHFFFAOYSA-N COc1cc(NC(C(c2c[nH]c3cc(F)ccc23)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 Chemical compound COc1cc(NC(C(c2c[nH]c3cc(F)ccc23)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 YTAWZGPWZPPXCQ-UHFFFAOYSA-N 0.000 description 1
- ZMVGWTDZWGPFNC-UHFFFAOYSA-N COc1cc(NC(C(c2c[nH]c3ccc(C(F)(F)F)cc23)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 Chemical compound COc1cc(NC(C(c2c[nH]c3ccc(C(F)(F)F)cc23)=O)c(ccc(Cl)c2)c2OC)cc(S(C)(=O)=O)c1 ZMVGWTDZWGPFNC-UHFFFAOYSA-N 0.000 description 1
- KQOARNWGKHKZFP-UHFFFAOYSA-N Cc(cc(c(C(C(c(ccc(Cl)c1)c1OC)Nc1cc(S(C)(=O)=O)cc(OC)c1)=O)c[nH]1)c1c1)c1F Chemical compound Cc(cc(c(C(C(c(ccc(Cl)c1)c1OC)Nc1cc(S(C)(=O)=O)cc(OC)c1)=O)c[nH]1)c1c1)c1F KQOARNWGKHKZFP-UHFFFAOYSA-N 0.000 description 1
- HKMBSMRJKCORQX-UHFFFAOYSA-N Cc1c2[nH]cc(C(C(c(ccc(Cl)c3)c3OC)Nc3cc(S(C)(=O)=O)cc(OC)c3)=O)c2ccc1OC Chemical compound Cc1c2[nH]cc(C(C(c(ccc(Cl)c3)c3OC)Nc3cc(S(C)(=O)=O)cc(OC)c3)=O)c2ccc1OC HKMBSMRJKCORQX-UHFFFAOYSA-N 0.000 description 1
- LNZLTXPBGCKAKK-UHFFFAOYSA-N Cc1cc(OC(F)(F)F)cc2c1[nH]cc2C(C(c(ccc(Cl)c1)c1OC)Nc1cc(S(C)(=O)=O)cc(OC)c1)=O Chemical compound Cc1cc(OC(F)(F)F)cc2c1[nH]cc2C(C(c(ccc(Cl)c1)c1OC)Nc1cc(S(C)(=O)=O)cc(OC)c1)=O LNZLTXPBGCKAKK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15166900.9 | 2015-05-08 | ||
| EP15166900 | 2015-05-08 | ||
| EP16163342 | 2016-03-31 | ||
| EP16163342.5 | 2016-03-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202041499A TW202041499A (zh) | 2020-11-16 |
| TWI744963B true TWI744963B (zh) | 2021-11-01 |
Family
ID=56026812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109121289A TWI744963B (zh) | 2015-05-08 | 2016-05-05 | 作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 |
| TW105113912A TWI725969B (zh) | 2015-05-08 | 2016-05-05 | 作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105113912A TWI725969B (zh) | 2015-05-08 | 2016-05-05 | 作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 |
Country Status (39)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| US9944598B2 (en) * | 2014-10-01 | 2018-04-17 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| BR112017006708A2 (pt) * | 2014-10-01 | 2017-12-26 | Janssen Pharmaceuticals Inc | indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20190531A (es) * | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| PH12022551160A1 (en) * | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| WO2022094817A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Pharmaceutical formulation |
| WO2022094816A1 (en) * | 2020-11-04 | 2022-05-12 | Janssen Pharmaceuticals, Inc. | Solid formulation |
| CN113024440B (zh) * | 2021-03-17 | 2023-05-16 | 凯莱英医药集团（天津）股份有限公司 | 连续化合成取代吲哚-2-羧酸的方法 |
| MX2023014787A (es) | 2021-06-29 | 2024-03-25 | Janssen Pharmaceuticals Inc | Procesos para la preparación de derivados de (s)-2-(4-cloro-2-meto xifenil)-2-(3-metoxi-5 (metilsulfonil)fenil)amino)- 1-(1h-indol-3-il)etenona. |
| CN119173261A (zh) | 2022-05-12 | 2024-12-20 | 杨森制药公司 | 登革热病毒感染的治疗和/或预防 |
| CN115521307B (zh) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | 一种5-卤代-7-氮杂吲哚的制备方法 |
| WO2025253267A1 (en) | 2024-06-06 | 2025-12-11 | Janssen Pharmaceuticals, Inc. | Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease |
| WO2026018176A1 (en) | 2024-07-17 | 2026-01-22 | Janssen Pharmaceuticals, Inc. | 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same |
| WO2026057013A1 (zh) * | 2024-09-14 | 2026-03-19 | 华武生物医药技术(湖北)有限责任公司 | 一类登革热病毒复制抑制剂、其制备方法和用途 |
| CN119306651B (zh) * | 2024-10-11 | 2025-12-05 | 山东大学 | 一种吲哚3-酰胺类衍生物及其制备方法与应用 |
| CN121378100B (zh) * | 2025-12-24 | 2026-04-21 | 浙江大学医学院附属第二医院 | 一种苯并[g]吲哚衍生物及其在制备抗登革热药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104024223A (zh) * | 2011-09-26 | 2014-09-03 | 鲁汶天主教大学 | 病毒复制抑制剂 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1200899A (en) | 1997-10-27 | 1999-05-17 | Eli Lilly And Company | Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| EP1519735A4 (en) | 2001-12-12 | 2006-01-11 | Conforma Therapeutic Corp | ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| CN101103026A (zh) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| AU2006221080A1 (en) | 2005-02-09 | 2006-09-14 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
| FR2928645A1 (fr) * | 2008-03-14 | 2009-09-18 | Sanofi Aventis Sa | Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| CN102056483A (zh) | 2008-06-03 | 2011-05-11 | 西佳技术公司 | 用于治疗或预防登革病毒感染的小分子抑制剂 |
| MX2011001872A (es) * | 2008-08-18 | 2011-05-23 | Univ Yale | Moduladores de mif. |
| EP2331499B1 (en) | 2008-08-19 | 2016-09-21 | Janssen Pharmaceutica NV | Cold menthol receptor antagonists |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| WO2010091413A1 (en) | 2009-02-09 | 2010-08-12 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| EA201290575A1 (ru) | 2010-01-15 | 2013-01-30 | Джилид Сайэнс, Инк. | Ингибиторы вирусов flaviviridae |
| WO2011120025A1 (en) | 2010-03-26 | 2011-09-29 | Glaxo Group Limited | Indazolyl-pyrimidines as kinase inhibitors |
| JP5716205B2 (ja) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法 |
| GB201305376D0 (en) | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| JP6505727B2 (ja) | 2014-01-31 | 2019-04-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環 |
| KR102382905B1 (ko) | 2014-06-04 | 2022-04-04 | 프레드 헛친슨 켄서 리서치 센터 | 노치 1 및/또는 노치 2 작용제를 사용한 줄기 세포의 확장 및 생착 |
| KR102391259B1 (ko) | 2014-06-04 | 2022-04-26 | 암젠 인크 | 포유류 세포 배양물을 회수하는 방법 |
| US9944598B2 (en) | 2014-10-01 | 2018-04-17 | Janssen Pharmaceuticals, Inc. | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |
| BR112017006708A2 (pt) | 2014-10-01 | 2017-12-26 | Janssen Pharmaceuticals Inc | indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue |
| NO2721243T3 (enExample) | 2014-10-01 | 2018-10-20 | ||
| ES2896198T3 (es) | 2014-10-10 | 2022-02-24 | Univ Rutgers | Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis |
| PH12017501272B1 (en) * | 2015-01-16 | 2023-01-11 | Janssen Pharmaceuticals Inc | Indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) * | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JP6636133B2 (ja) | 2015-07-22 | 2020-01-29 | オメイコス セラピューティクス ゲーエムベーハー | 心疾患の治療に対するｃｙｐ−エイコサノイドの代謝的にロバストな類縁体 |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3002214C (en) | 2015-11-03 | 2022-01-04 | Zoetis Services Llc | Sol-gel polymer composites and uses thereof |
| UY37174A (es) | 2016-03-31 | 2017-10-31 | Takeda Pharmaceuticals Co | Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| AU2017240801A1 (en) | 2016-04-01 | 2018-10-25 | Amgen Inc. | Chimeric receptors to FLT3 and methods of use thereof |
| US10576085B2 (en) | 2016-04-01 | 2020-03-03 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| KR102427334B1 (ko) | 2016-04-01 | 2022-08-03 | 카이트 파마 인코포레이티드 | 키메라 항원 및 t 세포 수용체 및 사용 방법 |
| SG10201912519VA (en) | 2016-04-01 | 2020-02-27 | Kite Pharma Inc | Chimeric receptors and methods of use thereof |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| MX2018012016A (es) | 2016-04-01 | 2019-01-24 | Basf Se | Compuestos biciclicos. |
| GB2573909B (en) | 2017-03-17 | 2020-05-20 | Mitsubishi Electric Corp | Adaptive array antenna device |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2016
- 2016-05-03 JO JOP/2016/0086A patent/JOP20160086B1/ar active
- 2016-05-04 RS RS20210800A patent/RS62029B1/sr unknown
- 2016-05-04 ES ES21159479T patent/ES2941674T3/es active Active
- 2016-05-04 ES ES16723965T patent/ES2877404T3/es active Active
- 2016-05-04 HU HUE16723965A patent/HUE054724T2/hu unknown
- 2016-05-04 UA UAA201909970A patent/UA128183C2/uk unknown
- 2016-05-04 SM SM20210367T patent/SMT202100367T1/it unknown
- 2016-05-04 CN CN202010168278.5A patent/CN111303000B/zh active Active
- 2016-05-04 EP EP16723965.6A patent/EP3294738B1/en active Active
- 2016-05-04 PE PE2017002377A patent/PE20180232A1/es unknown
- 2016-05-04 CN CN201680026606.XA patent/CN107873022B/zh active Active
- 2016-05-04 MX MX2020011156A patent/MX391754B/es unknown
- 2016-05-04 CN CN202110222667.6A patent/CN113045476B/zh active Active
- 2016-05-04 PL PL16723965T patent/PL3294738T3/pl unknown
- 2016-05-04 CA CA2981845A patent/CA2981845C/en active Active
- 2016-05-04 PE PE2021001440A patent/PE20221579A1/es unknown
- 2016-05-04 MX MX2017014293A patent/MX383932B/es unknown
- 2016-05-04 LT LTEP16723965.6T patent/LT3294738T/lt unknown
- 2016-05-04 HR HRP20210675TT patent/HRP20210675T1/hr unknown
- 2016-05-04 SI SI201631214T patent/SI3294738T1/sl unknown
- 2016-05-04 AU AU2016259677A patent/AU2016259677B2/en active Active
- 2016-05-04 UA UAA201711845A patent/UA121332C2/uk unknown
- 2016-05-04 BR BR112017023904-3A patent/BR112017023904A2/pt not_active Application Discontinuation
- 2016-05-04 EP EP21159479.1A patent/EP3896072B1/en active Active
- 2016-05-04 WO PCT/EP2016/059975 patent/WO2016180696A1/en not_active Ceased
- 2016-05-04 MD MDE20180272T patent/MD3294738T2/ro active IP Right Revival
- 2016-05-04 SG SG10201900315SA patent/SG10201900315SA/en unknown
- 2016-05-04 CR CR20200152A patent/CR20200152A/es unknown
- 2016-05-04 KR KR1020217011966A patent/KR102610493B1/ko active Active
- 2016-05-04 JP JP2017557923A patent/JP6752821B2/ja active Active
- 2016-05-04 CR CR20170490A patent/CR20170490A/es unknown
- 2016-05-04 KR KR1020177031660A patent/KR102610491B1/ko active Active
- 2016-05-04 EA EA201792429A patent/EA034978B1/ru unknown
- 2016-05-04 DK DK16723965.6T patent/DK3294738T3/da active
- 2016-05-04 US US15/571,930 patent/US10696632B2/en active Active
- 2016-05-04 MY MYPI2020005593A patent/MY198339A/en unknown
- 2016-05-05 TW TW109121289A patent/TWI744963B/zh active
- 2016-05-05 TW TW105113912A patent/TWI725969B/zh active
- 2016-05-06 UY UY0001039706A patent/UY39706A/es not_active Application Discontinuation
- 2016-05-06 UY UY0001036674A patent/UY36674A/es active IP Right Grant
-
2017
- 2017-11-01 SV SV2017005557A patent/SV2017005557A/es unknown
- 2017-11-02 GT GT201700234A patent/GT201700234A/es unknown
- 2017-11-02 PH PH12017502000A patent/PH12017502000B1/en unknown
- 2017-11-05 IL IL255430A patent/IL255430B/en active IP Right Grant
- 2017-11-07 CL CL2017002817A patent/CL2017002817A1/es unknown
- 2017-11-07 NI NI201700137A patent/NI201700137A/es unknown
- 2017-11-07 ZA ZA2017/07524A patent/ZA201707524B/en unknown
- 2017-11-07 EC ECIEPI201773878A patent/ECSP17073878A/es unknown
- 2017-11-30 CO CONC2017/0012381A patent/CO2017012381A2/es unknown
-
2020
- 2020-02-20 IL IL272814A patent/IL272814B/en active IP Right Grant
- 2020-04-13 JP JP2020071412A patent/JP6898493B2/ja active Active
- 2020-05-05 ZA ZA2020/02435A patent/ZA202002435B/en unknown
- 2020-05-13 US US15/930,738 patent/US10919854B2/en active Active
- 2020-11-19 AU AU2020273314A patent/AU2020273314B2/en active Active
- 2020-12-31 US US17/139,703 patent/US11827602B2/en active Active
-
2021
- 2021-05-10 JO JOJO/P/2021/0109A patent/JOP20210109B1/ar active
- 2021-06-09 JP JP2021096927A patent/JP7132399B2/ja active Active
- 2021-07-06 CY CY20211100607T patent/CY1124548T1/el unknown
-
2022
- 2022-03-25 EC ECSENADI202223220A patent/ECSP22023220A/es unknown
- 2022-08-24 JP JP2022133239A patent/JP7451626B2/ja active Active
-
2023
- 2023-10-19 US US18/490,072 patent/US12172959B2/en active Active
-
2024
- 2024-12-19 US US18/987,392 patent/US20250230127A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104024223A (zh) * | 2011-09-26 | 2014-09-03 | 鲁汶天主教大学 | 病毒复制抑制剂 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI725969B (zh) | 作為登革熱病毒複製抑制劑之單-或二-取代吲哚衍生物 | |
| TWI758255B (zh) | 作為登革熱病毒複製抑制劑之單-或二-取代之吲哚衍生物 | |
| TWI758256B (zh) | 作為登革熱病毒複製抑制劑之單取代或二取代吲哚衍生物 | |
| CN107001264B (zh) | 作为登革热病毒复制抑制剂的单取代的或二取代的吲哚衍生物 | |
| JP6830438B2 (ja) | デングウィルス複製阻害剤としてのインドール誘導体 | |
| HK1252446B (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | |
| HK1241874A1 (en) | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors |